AbbVie Inc. (NYSE:ABBV) Shares Acquired by First Command Advisory Services Inc.

First Command Advisory Services Inc. raised its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 23.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,807 shares of the company's stock after purchasing an additional 1,282 shares during the period. First Command Advisory Services Inc.'s holdings in AbbVie were worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of ABBV. GGM Financials LLC lifted its stake in shares of AbbVie by 0.7% in the 3rd quarter. GGM Financials LLC now owns 6,895 shares of the company's stock worth $1,362,000 after acquiring an additional 50 shares during the period. Dillon & Associates Inc. lifted its stake in shares of AbbVie by 0.8% in the 3rd quarter. Dillon & Associates Inc. now owns 6,914 shares of the company's stock worth $1,362,000 after acquiring an additional 52 shares during the period. WFA Asset Management Corp increased its holdings in shares of AbbVie by 0.8% in the 3rd quarter. WFA Asset Management Corp now owns 7,003 shares of the company's stock valued at $1,383,000 after purchasing an additional 55 shares in the last quarter. Physicians Financial Services Inc. increased its holdings in shares of AbbVie by 0.5% in the 4th quarter. Physicians Financial Services Inc. now owns 12,150 shares of the company's stock valued at $2,159,000 after purchasing an additional 55 shares in the last quarter. Finally, Carr Financial Group Corp increased its holdings in shares of AbbVie by 1.1% in the 3rd quarter. Carr Financial Group Corp now owns 5,274 shares of the company's stock valued at $1,041,000 after purchasing an additional 56 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on shares of AbbVie in a report on Friday, November 15th. They issued an "outperform" rating and a $205.00 price target for the company. Wells Fargo & Company increased their price target on shares of AbbVie from $195.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, February 3rd. Citigroup increased their price target on shares of AbbVie from $205.00 to $215.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Leerink Partnrs upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a report on Friday, November 22nd. Finally, Bank of America reiterated a "neutral" rating and issued a $191.00 price target on shares of AbbVie in a report on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $208.35.

AbbVie Trading Up 1.0 %

Shares of ABBV traded up $2.05 during mid-day trading on Thursday, hitting $205.06. The company had a trading volume of 5,692,933 shares, compared to its average volume of 5,871,798. The business's 50-day simple moving average is $183.75 and its 200-day simple moving average is $186.85. The company has a quick ratio of 0.55, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $207.32. The stock has a market cap of $362.00 billion, a PE ratio of 85.44, a P/E/G ratio of 1.62 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter last year, the firm earned $2.79 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.20%. AbbVie's dividend payout ratio is presently 273.33%.

Insider Buying and Selling

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares of the company's stock, valued at $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total transaction of $1,143,466.20. Following the transaction, the executive vice president now directly owns 22,381 shares in the company, valued at approximately $4,429,199.90. This trade represents a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.25% of the company's stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.